AbCellera Biologics (ABCL) Other Operating Expenses (2020 - 2026)

AbCellera Biologics (ABCL) has 7 years of Other Operating Expenses data on file, last reported at $6.8 million in Q1 2026.

• Quarterly Other Operating Expenses rose 28.27% year-over-year to $6.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $73.0 million (up 40.17% YoY) and the FY2025 annual result came in at $22.2 million, down 75.6% from the prior year.
• Other Operating Expenses rose to $6.8 million in Q1 2026, from -$2.6 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $77.9 million in Q3 2024 to a low of -$108.6 million in Q4 2024.
• A 5-year average of $15.5 million and a median of $9.3 million in 2023 frame the typical range for Other Operating Expenses.
• The widest YoY moves for Other Operating Expenses: up 746.33% in 2024, down 2964.84% in 2024.
• Tracing ABCL's Other Operating Expenses over 5 years: stood at $18.1 million in 2022, then tumbled by 119.62% to -$3.5 million in 2023, then tumbled by 2964.84% to -$108.6 million in 2024, then jumped by 97.57% to -$2.6 million in 2025, then jumped by 359.61% to $6.8 million in 2026.
• The last three Other Operating Expenses figures came in at $6.8 million (Q1 2026), -$2.6 million (Q4 2025), and $60.3 million (Q3 2025), per Business Quant data.